Ad
ACET Quote Trading Chart Adicet Bio Inc.
home / stock / acet / acet quote
Quote | Adicet Bio Inc. (NASDAQ:ACET)
| Last: | $0.9947 |
|---|---|
| Change Percent: | 10.58% |
| Open: | $0.91 |
| Close: | $0.8995 |
| High: | $1.01 |
| Low: | $0.9021 |
| Volume: | 491,809 |
| Last Trade Date Time: | 02/14/2025 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
ACET Last Twenty Trading Days
| Last | Open | Close | High | Low | Volume | Date |
|---|---|---|---|---|---|---|
| $0.9947 | $0.91 | $0.8995 | $1.01 | $0.9021 | 491,809 | 02-14-2025 |
| $0.8995 | $0.8657 | $0.8995 | $0.9 | $0.8513 | 304,002 | 02-13-2025 |
| $0.8665 | $0.89 | $0.8665 | $0.89 | $0.8384 | 507,416 | 02-12-2025 |
| $0.901 | $0.88 | $0.901 | $0.9026 | $0.855 | 630,617 | 02-11-2025 |
| $0.9 | $0.9657 | $0.9 | $0.98 | $0.884 | 927,292 | 02-10-2025 |
| $0.9652 | $1.06 | $0.9652 | $1.06 | $0.9597 | 1,325,090 | 02-07-2025 |
| $1.03 | $0.98 | $1.03 | $1.09 | $0.95 | 2,978,190 | 02-06-2025 |
| $1.01 | $0.9982 | $1.01 | $1.05 | $0.86 | 21,247,736 | 02-05-2025 |
| $0.9199 | $0.8967 | $0.9199 | $0.928 | $0.878825 | 187,721 | 02-04-2025 |
| $0.8975 | $0.867 | $0.8975 | $0.9099 | $0.85 | 184,850 | 02-03-2025 |
| $0.885 | $0.9 | $0.885 | $0.9036 | $0.87 | 108,747 | 01-31-2025 |
| $0.89 | $0.9 | $0.89 | $0.921 | $0.87 | 324,440 | 01-30-2025 |
| $0.902 | $0.91 | $0.902 | $0.9297 | $0.88 | 165,409 | 01-29-2025 |
| $0.8941 | $0.89 | $0.8941 | $0.91 | $0.8738 | 144,327 | 01-28-2025 |
| $0.91 | $0.9053 | $0.91 | $0.95 | $0.9013 | 90,028 | 01-27-2025 |
| $0.9218 | $0.9424 | $0.9218 | $0.95 | $0.9045 | 71,658 | 01-24-2025 |
| $0.9434 | $0.93 | $0.9434 | $0.96 | $0.9 | 283,678 | 01-23-2025 |
| $0.918 | $0.9477 | $0.918 | $0.9478 | $0.9059 | 146,195 | 01-22-2025 |
| $0.9389 | $0.92 | $0.9389 | $0.95 | $0.8897 | 217,307 | 01-21-2025 |
| $0.9084 | $0.91 | $0.9084 | $0.9271 | $0.88 | 215,836 | 01-20-2025 |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
2025-02-05 08:44:04 ET DENVER, Colo., Feb 05, 2025 ( 247marketnews.com )- Adicet Bio (NASDAQ: ACET ) stated that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to ADI-001 for the potential treatment of adult patients with refractory systemic lupus erythem...
-
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenh...
-
Adicet made significant progress in 2024 and is well-positioned for success in 2025: Advancing Phase 1 clinical trial evaluating ADI-001 across six autoimmune diseases; preliminary data in lupus nephritis (LN) patients anticipated in 1H25, data from other patient cohorts expected in 2H25 ...